儿童创伤性脑损伤中高渗盐水与甘露醇治疗的临床结局比较
这项前瞻性多中心队列研究纳入2018年6月1日至2022年12月31日期间28个儿童重症监护病房收治的445例中重度创伤性脑损伤患儿(GCS≤13分),比较3%高渗盐水与20%甘露醇治疗的死亡率和功能结局。高渗盐水组死亡率为7.1%(13/184),甘露醇组为11.0%(9/82),差异无统计学意义(P=0.34)。校正年龄、性别、虐待史、受伤至入院时间、24小时内最低GCS评分和硬膜外血肿后,两组死亡率、出院时PCPC评分及3个月GOS-E-Peds评分均无组间差异。作者认为需要未来大型多中心随机临床试验验证这些发现。
要点
- 儿童中重度TBI(GCS≤13分)中,高渗盐水组死亡率7.1%(13/184),甘露醇组11.0%(9/82),差异无统计学意义(P=0.34)。
- 校正年龄、性别、虐待史、受伤至入院时间、24小时内最低GCS评分和硬膜外血肿后,两组死亡率、出院PCPC评分和3个月GOS-E-Peds评分均无组间差异。
- 445例患儿中41.3%接受3%高渗盐水,18.4%接受20%甘露醇,15.5%接受两者,24.7%两者均未接受。
- 作者认为高渗盐水与甘露醇相比未增加生存率或改善功能结局,未来需大型多中心随机临床试验验证。
适用人群与场景
- 年龄<18岁、中重度创伤性脑损伤(GCS评分≤13分)、有颅内压升高风险的儿童。
- 研究在亚洲、拉丁美洲和欧洲的28个儿童重症监护病房进行,纳入时间为2018年6月1日至2022年12月31日。
诊断标准与关键阈值
- 中重度创伤性脑损伤定义为格拉斯哥昏迷评分(GCS)≤13分。
处置流程与药物剂量
- 暴露为使用3%高渗盐水或20%甘露醇治疗,具体剂量、给药途径和频次原文未报告。
研究设计与关键结果
- 前瞻性多中心队列研究,纳入445例中重度TBI患儿,中位年龄5.0岁(IQR 2.0-11.0),279例(62.7%)为男孩,344例(77.3%)为重度TBI。
- 184例(41.3%)接受3%高渗盐水,82例(18.4%)接受20%甘露醇,69例(15.5%)接受两者,110例(24.7%)两者均未接受。
- 高渗盐水组死亡率为7.1%(13/184),甘露醇组为11.0%(9/82),P=0.34。
- 校正年龄、性别、虐待史、受伤至入院时间、24小时内最低GCS评分和硬膜外血肿后,两组死亡率、出院PCPC评分和3个月GOS-E-Peds评分均无组间差异。
- 采用倾向性评分逆概率加权控制组间基线不平衡。
证据类型、等级与局限
- 证据类型:前瞻性多中心队列研究。
- 作者指出需要未来大型多中心随机临床试验验证这些发现。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在儿童中重度TBI伴颅内压升高风险时,使用3%高渗盐水与20%甘露醇相比未显示生存率或功能结局获益;作者认为需未来大型多中心随机临床试验验证。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: The use of hypertonic saline (HTS) vs mannitol in the control of elevated intracranial pressure (ICP) secondary to neurotrauma is debated.
OBJECTIVE: To compare mortality and functional outcomes of treatment with 3% HTS vs 20% mannitol among children with moderate to severe traumatic brain injury (TBI) at risk of elevated ICP.
DESIGN, SETTING, AND PARTICIPANTS: This prospective, multicenter cohort study was conducted between June 1, 2018, and December 31, 2022, at 28 participating pediatric intensive care units in the Pediatric Acute and Critical Care Medicine in Asia Network (PACCMAN) and the Red Colaborativa Pediátrica de Latinoamérica (LARed) in Asia, Latin America, and Europe. The study included children (aged <18 years) with moderate to severe TBI (Glasgow Coma Scale [GCS] score ≤13).
EXPOSURE: Treatment with 3% HTS compared with 20% mannitol.
MAIN OUTCOMES AND MEASURES: Multiple log-binomial regression analysis was performed for mortality, and multiple linear regression analysis was performed for discharge Pediatric Cerebral Performance Category (PCPC) scores and 3-month Glasgow Outcome Scale-Extended Pediatric Version (GOS-E-Peds) scores. Inverse probability of treatment weighting was also performed using the propensity score method to control for baseline imbalance between groups.
RESULTS: This study included 445 children with a median age of 5.0 (IQR, 2.0-11.0) years. More than half of the patients (279 [62.7%]) were boys, and 344 (77.3%) had severe TBI. Overall, 184 children (41.3%) received 3% HTS, 82 (18.4%) received 20% mannitol, 69 (15.5%) received both agents, and 110 (24.7%) received neither agent. The mortality rate was 7.1% (13 of 184 patients) in the HTS group and 11.0% (9 of 82 patients) in the mannitol group (P = .34). After adjusting for age, sex, presence of child abuse, time between injury and hospital arrival, lowest GCS score in the first 24 hours, and presence of extradural hemorrhage, no between-group differences in mortality, hospital discharge PCPC scores, or 3-month GOS-E-Peds scores were observed.
CONCLUSIONS AND RELEVANCE: In this cohort study of children with moderate to severe TBI, the use of HTS was not associated with increased survival or improved functional outcomes compared with mannitol. Future large multicenter randomized clinical trials are required to validate these findings.
参考来源
- Chong SL, Zhu Y, Wang Q, et al. Clinical Outcomes of Hypertonic Saline vs Mannitol Treatment Among Children With Traumatic Brain Injury. JAMA Netw Open. 2025. PMID: 40067302. doi:10.1001/jamanetworkopen.2025.0438
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。